Hematological Malignancies [clinicaltrials_resource:57cb40309f10ef1dd19771a6d5168581]
Study of ABT-751 in Patients With Refractory Hematologic Malignancies [clinicaltrials:NCT00047489]STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors [clinicaltrials:NCT00088101]MiniMUD Study - Unrelated Reduced Intensity Conditioning With TreosulfanĀ® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies [clinicaltrials:NCT00129155]RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT [clinicaltrials:NCT00163644]Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) [clinicaltrials:NCT00179764]An Evaluation of the Effect of 'Open Window' on Psychological Well-being and Experience of Stem Cell Transplantation [clinicaltrials:NCT00348959]clinicaltrials:NCT00379587Nonmyeloablative Stem Cell Transplant in Elderly [clinicaltrials:NCT00382759]Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies [clinicaltrials:NCT00423124]Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies [clinicaltrials:NCT00438178]clinicaltrials:NCT00500578Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease [clinicaltrials:NCT00504803]A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies [clinicaltrials:NCT00506402]clinicaltrials:NCT00506948Open-Label Study Designed to Evaluate the Safety and Preliminary Efficacy of ApoCell for the Prevention of Acute GvHD [clinicaltrials:NCT00524784]Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT) [clinicaltrials:NCT00557817]Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies [clinicaltrials:NCT00580450]Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings [clinicaltrials:NCT00603954]clinicaltrials:NCT00763490Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers [clinicaltrials:NCT00788684]Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients [clinicaltrials:NCT00824993]Intrabone Cord Blood Transplantation [clinicaltrials:NCT00838019]Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies [clinicaltrials:NCT00841724]Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting [clinicaltrials:NCT00876148]Exercise During Chemotherapy for Patients With Hematological Malignancies [clinicaltrials:NCT00884364]clinicaltrials:NCT00886522Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? [clinicaltrials:NCT00892502]Extracorporal Photopheresis Pilot Study [clinicaltrials:NCT00930566]Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients [clinicaltrials:NCT01060462]Dose-range Finding Treosulfan-based Conditioning [clinicaltrials:NCT01063647]A Prospective Registry for Febrile Events in Patients With Malignant Hemopathies or Subjected to Haematopoietic Stem Cell Transplant [clinicaltrials:NCT01069887]Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3) [clinicaltrials:NCT01139164]clinicaltrials:NCT01162096Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies [clinicaltrials:NCT01168882]The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH" [clinicaltrials:NCT01172132]Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB) [clinicaltrials:NCT01235468]Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT [clinicaltrials:NCT01246206]clinicaltrials:NCT01315132clinicaltrials:NCT01349101clinicaltrials:NCT01428973
condition [clinicaltrials_vocabulary:condition]
Hematological Malignancies [clinicaltrials_resource:57cb40309f10ef1dd19771a6d5168581]
Bio2RDF identifier
57cb40309f10ef1dd19771a6d5168581
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:57cb40309f10ef1dd19771a6d5168581
identifier
clinicaltrials_resource:57cb40309f10ef1dd19771a6d5168581
title
Hematological Malignancies
@en
label
Hematological Malignancies [clinicaltrials_resource:57cb40309f10ef1dd19771a6d5168581]
@en